Rhumbline Advisers Kura Oncology, Inc. Transaction History
Rhumbline Advisers
- $113 Billion
- Q2 2025
A detailed history of Rhumbline Advisers transactions in Kura Oncology, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 118,896 shares of KURA stock, worth $1.2 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
118,896
Previous 105,206
13.01%
Holding current value
$1.2 Million
Previous $694,000
1.15%
% of portfolio
0.0%
Previous 0.0%
Shares
33 transactions
Others Institutions Holding KURA
# of Institutions
190Shares Held
79.8MCall Options Held
53.6KPut Options Held
42.8K-
Suvretta Capital Management, LLC New York, NY8.12MShares$81.8 Million1.61% of portfolio
-
Bvf Inc San Francisco, CA7.75MShares$78.2 Million1.76% of portfolio
-
Black Rock Inc. New York, NY6.97MShares$70.2 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY6.2MShares$62.5 Million0.63% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.35MShares$53.9 Million0.0% of portfolio
About Kura Oncology, Inc.
- Ticker KURA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 66,893,000
- Market Cap $674M
- Description
- Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A p...